PCM
MDGL icon

Prelude Capital Management’s Madrigal Pharmaceuticals MDGL Stock Holding History

Prelude Capital Management’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-2,800
Closed -$293K – 1912
2019
Q2 		$293K Buy
2,800
+100
+4% +$10.7K 0.01% 625
2019
Q1 		$338K Buy
+2,700
New +$336K 0.02% 578
2018
Q4 		– Sell
-4,500
Closed -$964K – 2017
2018
Q3 		$964K Buy
+4,500
New +$1.13M 0.06% 379

Other funds holding MDGL

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Prelude Capital Management's MDGL Position: Q1 2026 in Review

Prelude Capital Management sold out of Madrigal Pharmaceuticals (MDGL) in Q1 2026, closing a stake of 430 shares — an estimated $250K sold.

Prelude Capital Management first reported a position in MDGL in Q2 2018 and held it in 7 quarters. The position peaked at $700K in Q2 2024. 378 funds tracked by Wall St. Rank hold MDGL as of Q1 2026.

  • Prelude Capital Management reported no remaining Madrigal Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Prelude Capital Management sold 430 Madrigal Pharmaceuticals shares in Q1 2026, an estimated $250K.
  • Prelude Capital Management first reported a position in Madrigal Pharmaceuticals in Q2 2018 and held it in 7 quarters.
  • Prelude Capital Management's Madrigal Pharmaceuticals position peaked at $700K in Q2 2024.
  • 378 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q1 2026.

Based on Prelude Capital Management's 13F filing for Q1 2026, filed 15 May 2026.